<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04037085</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY18120046</org_study_id>
    <nct_id>NCT04037085</nct_id>
  </id_info>
  <brief_title>Ketamine to Improve Recovery After Cesarean Delivery - Part 1</brief_title>
  <acronym>KINETIC</acronym>
  <official_title>Evaluation of PK/PD, Breastmillk Transfer, and Effectiveness of Ketamine After Cesarean Delivery - Part 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grace Lim, MD, MS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is evaluate the breastmilk transfer and pharmacokinetics (Part 1)
      and effectiveness (Part 2) of a post-cesarean delivery intravenous ketamine
      bolus-and-infusion strategy, as a preventive analgesic modality to reduce pain and opioid
      requirements. Physiochemical, PK/PD, and breastmilk transfer of ketamine and its metabolites,
      as well as calculated estimations for neonatal exposure will be assessed in Part 1. In Part
      2, PK/PD assessments will continue in a larger cohort. Endpoints will also include postpartum
      pain, depression scores, central sensitization measures, patient-reported postpartum recovery
      scores, breastfeeding, and parent-infant bonding, assessed in the acute post-cesarean period
      and up to 12 weeks postpartum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postpartum pain management strategies currently permit opioids for breakthrough pain, but
      strategies focused on minimizing or eliminating opioids are lacking. In the non-obstetric
      surgical population, modalities such as intravenous ketamine are well-recognized as effective
      adjuncts in opioid-reduction strategies for postoperative pain. Although there have been some
      studies of ketamine exposure in postpartum women without deleterious outcomes noted, these
      studies in pregnant and lactating women are limited by a lack of information on maternal
      pharmacokinetics, breastmilk secretion, and clinical effectiveness when used with standard
      multimodal analgesic approaches. There is also a lack of information on intermediate and
      long-term outcomes in this setting. This two-part trial will address these knowledge gap by
      advancing understanding of the safety and efficacy of ketamine and its metabolites in
      perinatal populations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective observational open-label trial (Part 1)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ketamine (AUC)</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>Breast milk, colostrum, plasma will be used to calculate plasma milk area under the curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ketamine (M:P)</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>M:P ratio will be calculated from milk and plasma levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ketamine (AID)</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>Absolute infant dose will be calculated from breastmilk</description>
  </primary_outcome>
  <primary_outcome>
    <measure>S-ketamine</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>Maternal urine, serum, and breast milk will be used to measure concentrations of ketamine metabolites in these substances</description>
  </primary_outcome>
  <primary_outcome>
    <measure>norketamine</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>Maternal urine, serum, and breast milk will be used to measure concentrations of ketamine metabolites in these substances</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hydroxyl-ketamine</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>Maternal urine, serum, and breast milk will be used to measure concentrations of ketamine metabolites in these substances</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hydroxynorketamine</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>Maternal urine, serum, and breast milk will be used to measure concentrations of ketamine metabolites in these substances</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady state (Css)</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>Postpartum maternal urine, serum will be used to calculate postpartum maternal ketamine steady state (Css)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life (T1/2)</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>Postpartum maternal urine, serum will be used to calculate postpartum maternal ketamine half-life (T1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>Postpartum maternal urine, serum will be used to calculate postpartum maternal ketamine volume of distribution (VD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Milligram morphine equivalents (MME)</measure>
    <time_frame>72 hours postpartum</time_frame>
    <description>MME consumed in the first 72 hours postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static, dynamic, and affective VAS pain score</measure>
    <time_frame>72 hours</time_frame>
    <description>Pain ratings at rest and with movement and affective pain on a 100mm line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic acute pain</measure>
    <time_frame>72 hours postpartum</time_frame>
    <description>Pain ratings with movement on a 0-100mm line, visual analog scale where 0 is no pain and 100 is the most pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - blood pressure</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>blood pressure will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - heart rate</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>heart rate will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - oxygen saturation</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>oxygen saturation will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - respiratory rate</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>respiratory rate will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>Richmond agitation sedation scale (RASS) scale. -3 or less is moderate to unarousable sedation. -2 to 0 is calm to light sedation. +1 to +4 is restless to combative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>27 hours postpartum</time_frame>
    <description>LSD scale, dizziness, lightheadedness, bad dreams, nausea, vomiting, pruritus, hallucinations</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Obstetric Pain</condition>
  <condition>Postpartum Depression</condition>
  <condition>Breastfeeding</condition>
  <condition>Pain, Acute</condition>
  <condition>Pain, Chronic</condition>
  <condition>Obstetric Anesthesia Problems</condition>
  <condition>Drug Effect</condition>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine - IV after cord clamping; IV infusion for 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Subjects in the intervention arm will receive bolus and infusion dosing as noted in arm/group descriptions at the time of cord clamping. Duration of infusion will be 12 hours. Breastmilk, maternal serum and urine, side effects, adverse events, and efficacy endpoints will be measured over the 12 hour infusion and over 15 hours after infusion discontinuation.</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult female patients (i.e., â‰¥18 years of age) and able to provide informed consent

          -  Cesarean Delivery, Scheduled or Non-Emergent (delivery within 15 minutes not
             necessary)

          -  Primary or repeat cesarean delivery

          -  &gt;/=37 weeks gestation

          -  ASA PS 2 or 3, with or without E designation (delivery within 15 minutes not
             necessary)

          -  Spinal anesthesia with intrathecal morphine

          -  Multimodal postop analgesia with IV ketorolac, PO NSAID, and PO APAP

          -  Women who do not plan to breastfeed or are temporarily withholding breastfeeding (Part
             1)

        Exclusion Criteria:

          -  Cesarean Delivery under General Anesthesia

          -  Allergies to study medications

          -  ASA PS 4 or 4E

          -  ASA PS with E designation because delivery within 15 minutes required

          -  ASA PS greater than 4 (moribund patients)

          -  Contraindications to spinal anesthesia

          -  Contraindications to NSAIDs (gastric bypass, etc.)

          -  Contraindication to any other multimodal analgesia medicine

          -  Significant psychiatric history, uncontrolled hyperthyroidism, cardiac disease, fever,
             hypertension

          -  Adverse occurrence during caesarean section such as hemorrhage, need for transfusion,
             hemodynamic instability

          -  Placenta accreta or previa with large anticipated blood loss

          -  History of hallucinations, alcohol or illicit substance use/abuse, chronic opioid
             therapy, or chronic pain

          -  Pre-eclampsia with severe features
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace Lim, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelsea LaSorda</last_name>
    <phone>412-641-2179</phone>
    <email>lasordakr@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Monroe</last_name>
    <phone>412-623-6382</phone>
    <email>monroeal@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC Magee Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsea LaSorda, MPH</last_name>
      <phone>412-641-2179</phone>
      <email>lasordakr@upmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Grace Lim, MD, MS</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression, Postpartum</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Labor Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

